Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

237
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
237
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

1.4K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.4K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

25
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
25
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

24
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
24
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

33
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
33
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

89
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
89

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Letter: Therapeutic Targeting of PPARs in PBC-Additional Considerations. Authors' Reply.

Alimentary pharmacology & therapeutics·2026
Same author

Integrated multi-omics identifies distinct macrophage alterations during progression of metabolic dysfunction-associated steatohepatitis.

Nature genetics·2026
Same author

The spectrum of steatotic liver disease (SLD) in cardiology - time to screen for coexisting liver disease.

European journal of heart failure·2026
Same author

Review Article: An Update on Non-Invasive Tests for Steatotic Liver Disease - Insights From the ESSENCE Phase 3 Trial and Longitudinal Studies.

Alimentary pharmacology & therapeutics·2026
Same author

Review Article: Targeting Peroxisome Proliferator-Activated Receptors in Primary Biliary Cholangitis.

Alimentary pharmacology & therapeutics·2026
Same author

Effect of Essential Phospholipids in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomised Phase 4 Clinical Trial.

Liver international : official journal of the International Association for the Study of the Liver·2026

Related Experiment Video

Updated: Oct 19, 2025

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.1K

NAFLD in the Elderly.

Saleh A Alqahtani1,2, Jörn M Schattenberg3

  • 1Liver Transplantation Center, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia.

Clinical Interventions in Aging
|September 22, 2021
PubMed
Summary

Non-alcoholic fatty liver disease (NAFLD) affects one billion people globally. This review focuses on diagnosing and managing NAFLD and non-alcoholic steatohepatitis (NASH) in older adults, considering age-specific factors.

Keywords:
NASHagingfatty liverliver diseaseregenerationsenescence

More Related Videos

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.4K
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

16.2K

Related Experiment Videos

Last Updated: Oct 19, 2025

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.1K
Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.4K
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

16.2K

Area of Science:

  • Hepatology
  • Geriatrics
  • Internal Medicine

Background:

  • Non-alcoholic fatty liver disease (NAFLD) is a global health concern with a 24% prevalence in adults.
  • NAFLD prevalence peaks in middle-aged and older adults, with increased risk factors like diabetes and obesity in this demographic.
  • Diagnosis and management of NAFLD in older adults present unique challenges requiring age-specific considerations.

Purpose of the Study:

  • To review diagnostic considerations for NAFLD in individuals over 65 years.
  • To outline management strategies for NAFLD and non-alcoholic steatohepatitis (NASH) in the aging population.
  • To discuss available pharmacological interventions for NASH in older adults.

Main Methods:

  • Systematic literature review of NAFLD and NASH in older adults.
  • Analysis of age-specific risk factors and clinical presentation.
  • Evaluation of current and emerging pharmacological treatments.

Main Results:

  • Older adults present unique challenges in NAFLD diagnosis and management.
  • Age-related comorbidities like hypertension, diabetes, and obesity are prevalent in older NAFLD patients.
  • Pharmacological interventions for NASH require careful consideration of safety and efficacy in the elderly.

Conclusions:

  • NAFLD diagnosis and management in older adults necessitate tailored approaches.
  • Healthcare professionals must account for age-specific factors when treating NAFLD and NASH in the elderly.
  • Further research is needed to optimize pharmacological therapies for NASH in aging populations.